Background: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer generally diagnosed at an advanced stage and characterized by a poor prognosis. The absence of alterations in druggable kinases, together with an immune-suppressive tumor microenvironment, limits the use of molecular targeted therapies, making the treatment of MPM particularly challenging. Here we investigated the in vitro susceptibility of MPM to lurbinectedin (PM01183), a marine-derived drug that recently received accelerated approval by the FDA for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. Methods: A panel of primary MPM cultures, resembling the three major MPM histological subtypes (epithelioid, sarcomatoid, and biphasic), was characterized in terms of BAP1 status and histological markers. Subsequently, we explored the effects of lurbinectedin at nanomolar concentration on cell cycle, cell viability, DNA damage, genotoxic stress response, and proliferation. Results: Stabilized.

Evaluation of the preclinical efficacy of lurbinectedin in malignant pleural mesothelioma

Anobile D. P.;Bironzo P.;Picca F.;Lingua M. F.;Morena D.;Righi L.;Napoli F.;Papotti M. G.;Di Nicolantonio F.;Gigliotti C.;Bussolino F.;Comunanza V.;Guerrera F.;Sandri A.;Leo F.;Novello S.;Taulli R.;Scagliotti G. V.;Riganti C.
2021

Abstract

Background: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer generally diagnosed at an advanced stage and characterized by a poor prognosis. The absence of alterations in druggable kinases, together with an immune-suppressive tumor microenvironment, limits the use of molecular targeted therapies, making the treatment of MPM particularly challenging. Here we investigated the in vitro susceptibility of MPM to lurbinectedin (PM01183), a marine-derived drug that recently received accelerated approval by the FDA for the treatment of patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. Methods: A panel of primary MPM cultures, resembling the three major MPM histological subtypes (epithelioid, sarcomatoid, and biphasic), was characterized in terms of BAP1 status and histological markers. Subsequently, we explored the effects of lurbinectedin at nanomolar concentration on cell cycle, cell viability, DNA damage, genotoxic stress response, and proliferation. Results: Stabilized.
13
10
///
///
DNA damage response; Lurbinectedin; MPM
Anobile D.P.; Bironzo P.; Picca F.; Lingua M.F.; Morena D.; Righi L.; Napoli F.; Papotti M.G.; Pittaro A.; Di Nicolantonio F.; Gigliotti C.; Bussolino F.; Comunanza V.; Guerrera F.; Sandri A.; Leo F.; Libener R.; Aviles P.; Novello S.; Taulli R.; Scagliotti G.V.; Riganti C.
File in questo prodotto:
File Dimensione Formato  
cancers-13-02332-v2.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 3.78 MB
Formato Adobe PDF
3.78 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1790637
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact